$TELO News

Telomir Pharma Announces Peer-Reviewed Publication Of Preclinical Data Showing Telomir-Zn Produced Dose-Dependent Survival Improvement Across Multiple Endpoints In Wilson's Disease Model

EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study

Telomir Pharmaceuticals Submits Investigational New Drug Application To FDA To Treat Advanced And Metastatic Triple-Negative Breast Cancer

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

Telomir Reveals New Data Showing Broad Tumor Cell Mortality In Distinct Triple-Negative Breast Cancer

Telomir Reveals New Data Showing Broad Tumor Cell Mortality In Distinct Triple-Negative Breast Cancer

Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

Telomir Pharmaceuticals Announces New Data Supporting Telomir-Zn's Mechanism In Cancer And Aging, Plans Submission For Investigational New Drug Application In Q1 2026

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

Telomir Pharmaceuticals Results From Trial In Zebrafish Tumor Xenograft Animal Models Of Triple-Negative Breast Cancer Shows Reductions In Primary Tumor Growth, Spread Of Cancer Cells

Telomir Pharmaceuticals Announces Results From Efficacy Study Of Telomir-1 In Animal Showing Reduced Tumor Growth And Metastases in Aggressive Triple-Negative Breast Cancer

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

Telomir Pharma Announces Results From Comprehensive Series Of IND-Enabling GLP Toxicology And Safety Pharmacology Studies For Telomir-1

Telomir Pharmaceuticals Announces Results From Good Laboratory Practice Studies For Telomir-1; Says Telomir-1 Was Generally Well Tolerated, With No Treatment-related Adverse Or Dose-limiting Toxicities Observed. Observed Findings Were Limited, Reversible, And Considered Non-adverse

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

Telomir Pharma Reports New Preclinical Findings Demonstrating Its Lead Therapeutic Candidate, Telomir-1, Reduced PSA Levels In Androgen-Responsive Human Prostate Cancer Cells

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

Telomir Pharmaceuticals Reports Telomir-1 Kills Aggressive Human Leukemia Cells In Preclinical In Vitro Study Expanding Oncology Profile To Blood Cancers

Telomir Pharmaceuticals Announces Telomir-1 Shown To Kill Aggressive Human Leukemia Cells

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line